Finance

Lists
Why is EMCURE down 2.85%?
Dive Deeper
EMCURE:NSE
Emcure Pharmaceuticals Ltd
₹1,768.80
-2.85%
(-51.80) 1D
Oct 19, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for EMCURE...
Open
₹1,801.00
High
₹1,829.00
Low
₹1,746.50
Mkt. cap
335.46B
Avg. vol.
174.44K
Volume
108.21K
Dividend
0.20%
Quarterly dividend
₹0.90
Ex-dividend date
Sep 4, 2026
P/E ratio
33.15
52-wk high
₹2,100.70
52-wk low
₹1,306.50
EPS
₹53.35
No. of employees
7K
Open
₹1,801.00
High
₹1,829.00
Low
₹1,746.50
Mkt. cap
335.46B
Avg. vol.
174.44K
Volume
108.21K
Dividend
0.20%
Quarterly dividend
₹0.90
Ex-dividend date
Sep 4, 2026
P/E ratio
33.15
52-wk high
₹2,100.70
52-wk low
₹1,306.50
EPS
₹53.35
No. of employees
7K
News stories
From web sources and news partners
Profile
Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company, headquartered in Pune. Emcure's product portfolio includes tablets, capsules and injectables. The company produces gynaecology, cardiovascular, oncology and blood therapeutic drugs, HIV antivirals and other anti-infectives, and vitamins and minerals. Wikipedia
About Emcure Pharmaceuticals Ltd
CEOSatish Ramanlal Mehta
Employees6.91K
FoundedApr 16, 1981
Headquarters-
SectorPharmaceutical industry
Websiteemcure.com
Next call in 14 days
Tue, Nov 3, 12:30 PM
Fiscal period
Q2 2027
- / ₹14.90
Revenue / Est. (INR)
- / 26.52B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
22.70B
23.63B
24.70B
25.80B
Cost of goods sold
8.90B
9.62B
10.93B
10.73B
Cost of revenue
8.90B
9.62B
10.93B
10.73B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.85B
3.87B
7.21B
4.09B
Operating expense
10.46B
10.46B
9.97B
11.09B
Total operating expenses
19.35B
20.08B
20.90B
21.82B
Operating income
3.34B
3.55B
3.79B
3.98B
Other non operating income
31.23M
18.53M
-363.67M
20.71M
EBT including unusual items
3.41B
3.14B
3.41B
3.94B
EBT excluding unusual items
3.41B
3.52B
3.72B
3.92B
Income tax expense
900.47M
824.22M
974.40M
1.01B
Effective tax rate
26.37%
26.27%
28.56%
25.67%
Other operating expenses
5.57B
5.54B
1.70B
5.90B
Net income
2.43B
2.31B
2.43B
2.94B
Net profit margin
10.73%
9.75%
9.86%
11.39%
Earnings per share
12.85
13.67
14.70
15.34
Interest and investment income
-
-
16.83M
-
Interest expense
-325.42M
-379.75M
-92.49M
-315.36M
Net interest expenses
-325.42M
-379.75M
-75.66M
-315.36M
Depreciation and amortization charges
1.05B
1.05B
1.06B
1.10B
EBITDA
4.37B
4.37B
4.67B
5.02B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps